Abstract
The discovery and clinical development of heat shock protein 90 (Hsp90) inhibitors continue to progress. A number of Hsp90 inhibitors are in clinical trials, and preclinical discoveries of new chemotypes that bind to distinct regions in the protein as well as isoform selective compounds are active areas of research. This review will highlight progress in the field since 2010.
Original language | English |
---|---|
Pages (from-to) | 8718-8728 |
Number of pages | 11 |
Journal | Journal of Medicinal Chemistry |
Volume | 57 |
Issue number | 21 |
DOIs | |
State | Published - 13 Nov 2014 |